6-OHDA mediated neurotoxicity in SH-SY5Y cellular model of Parkinson disease suppressed by pretreatment with hesperidin through activating L-type calcium channels.
Ca2+ hemostasis
Parkinson’s disease
hesperidin
Journal
Journal of basic and clinical physiology and pharmacology
ISSN: 2191-0286
Titre abrégé: J Basic Clin Physiol Pharmacol
Pays: Germany
ID NLM: 9101750
Informations de publication
Date de publication:
14 Sep 2020
14 Sep 2020
Historique:
received:
03
12
2019
accepted:
11
06
2020
pubmed:
13
9
2020
medline:
5
2
2022
entrez:
12
9
2020
Statut:
epublish
Résumé
Parkinson's disease (PD) is a neurological condition with selective progressive degeneration of dopaminergic neurons. Routine therapies are symptomatic and palliative. Although, hesperidin (Hsd) is known for its neuroprotective effects, its exact cellular mechanism is still a mystery. Considering the important role of calcium (Ca SH-SY5Y cell line was used in this study; cell damage was induced by 150 µM 6-OHDA and the cells' viability was examined using MTT assay. Intracellular calcium, reactive oxygen species (ROS) and mitochondrial membrane potential were determined by the fluorescence spectrophotometry method. The expressions of calcium channel receptors were determined by gel electrophoresis and immunoblotting. Loss of cell viability and mitochondrial membrane potential were confirmed in 6-OHDA treated cells. In addition, intracellular ROS and calcium levels, calcium channel receptors significantly increased in 6-OHDA-treated cells. Incubation of SH-SY5Y cells with hesperidin showed a protective effect, reduced the biochemical markers of cell damage/death, and balanced calcium hemostasis. Based on our findings, it seems that hesperidin could suppress the progression of the cellular model of PD via acting on intracellular calcium homeostasis. Further studies are needed to confirm the potential benefits of preventive and therapeutic effects of stabilizing cellular calcium homeostasis in neurodegenerative disease.
Identifiants
pubmed: 32918805
doi: 10.1515/jbcpp-2019-0270
pii: /j/jbcpp.ahead-of-print/jbcpp-2019-0270/jbcpp-2019-0270.xml
doi:
Substances chimiques
Calcium Channels, L-Type
0
Neuroprotective Agents
0
Reactive Oxygen Species
0
Oxidopamine
8HW4YBZ748
Hesperidin
E750O06Y6O
Calcium
SY7Q814VUP
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11-17Informations de copyright
© 2020 Walter de Gruyter GmbH, Berlin/Boston.
Références
Tysnes, O-B, Storstein, A. Epidemiology of Parkinson’s disease. J Neural Transm 2017;124:901–5. https://doi.org/10.1007/s00702-017-1686-y.
Mhyre, TR, Boyd, JT, Hamill, RW, Maguire-Zeiss, KA. Parkinson’s disease. Subcell Biochem 2012;65:389–455. https://doi.org/10.1007/978-94-007-5416-4_16.
Sulzer, D, Surmeier, DJ. Neuronal vulnerability, pathogenesis, and Parkinson’s disease. Mov Disord 2013;28:715–24. https://doi.org/10.1002/mds.25187.
Yacoubian, TA, Standaert, DG. Targets for neuroprotection in Parkinson’s disease. Biochim Biophys Acta (BBA) – Mol Basis Dis 2009;1792:676–87. https://doi.org/10.1016/j.bbadis.2008.09.009.
Magalingam, KB, Radhakrishnan, AK, Haleagrahara, N. Protective mechanisms of flavonoids in Parkinson’s disease. Oxid Med Cell Longev 2015;2015. https://doi.org/10.1155/2015/314560.
Corona, JC. Natural compounds for the management of Parkinson’s disease and attention-deficit/hyperactivity disorder. BioMed Res Int 2018;2018. https://doi.org/10.1155/2018/4067597.
Parhiz, H, , Roohbakhsh, A, Soltani, F, Rezaee, R, Iranshahi, M. Antioxidant and anti‐inflammatory properties of the citrus flavonoids hesperidin and hesperetin: an updated review of their molecular mechanisms and experimental models. Phytother Res 2015;29:323–31. https://doi.org/10.1002/ptr.5256.
Li, C, Schluesener, H. Health-promoting effects of the citrus flavanone hesperidin. Crit Rev Food Sci Nutr 2017;57:613–31. https://doi.org/10.1080/10408398.2014.906382.
Antunes, MS, Goes, AT, Boeira, SP, Prigol, M, Jesse, CR, et al. Protective effect of hesperidin in a model of Parkinson’s disease induced by 6-hydroxydopamine in aged mice. Nutrition 2014;30:1415–22. https://doi.org/10.1016/j.nut.2014.03.024.
Poetini, MR, Araujo, SM, Trindade de Paula, M, Bortolotto, VC, Meichtry, LB, Polet de Almeida, F, et al. Hesperidin attenuates iron-induced oxidative damage and dopamine depletion in Drosophila melanogaster model of Parkinson’s disease. Chem Biol Interact 2018;279:177–86. https://doi.org/10.1016/j.cbi.2017.11.018.
Hajialyani, M, Hosein Farzaei, M, Echeverría, J, Nabavi, SM, Uriarte, E, Sobarzo-Sánchez, E. Hesperidin as a neuroprotective agent: a review of animal and clinical evidence. Molecules 2019;24. https://doi.org/10.3390/molecules24030648.
Zaichick, SV, McGrath, KM, Caraveo, G. The role of Ca2+ signaling in Parkinson’s disease. Dis Models Mech 2017;10:519–35. https://doi.org/10.1242/dmm.028738.
Surmeier, DJ, Guzman, JN, Sanchez-Padilla, J. Calcium, cellular aging, and selective neuronal vulnerability in Parkinson’s disease. Cell Calcium 2010;47:175–82. https://doi.org/10.1016/j.ceca.2009.12.003.
Pasternak, B, Svanström, H, Nielsen, NM, Fugger, L, Melbye, M, Hviid, A. Use of calcium channel blockers and Parkinson’s disease. Am J Epidemiol 2012;175:627–35. https://doi.org/10.1093/aje/kwr362.
Ritz, B, Rhodes, SL, Qian, L, Schernhammer, E, Olsen, JH, Friis, S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol 2010;67:600–6.
Betzer, C, Lassen, LB, Olsen, A, Kofoed, RH, Reimer, L, Gregersen, E, et al. Alpha-synuclein aggregates activate calcium pump SERCA leading to calcium dysregulation. EMBO Rep 2018;19. https://doi.org/10.15252/embr.201744617.
Elyasi, L, Jahanshahi, M, Ghazvini, H, Nikmahzar, E. The protective effects of citrus aurantium flower extract against 6-hydroxydopamine-mediated cell damage in human neuroblastoma SH-SY5Y cells. Int J Morphol 2018;36. https://doi.org/10.4067/s0717-95022018000200435.
Boix, J, Padel, T, Paul, G. A partial lesion model of Parkinson’s disease in mice–Characterization of a 6-OHDA-induced medial forebrain bundle lesion. Behav Brain Res 2015;284:196–206. https://doi.org/10.1016/j.bbr.2015.01.053.
Elyasi, L, Eftekhar-Vaghefi, SH, Esmaeili-Mahani, S. Morphine protects SH-SY5Y human neuroblastoma cells against 6-hydroxydopamine-induced cell damage: involvement of anti-oxidant, calcium blocking, and anti-apoptotic properties. Rejuvenation Res 2014;17:255–63. https://doi.org/10.1089/rej.2013.1473.
Li, Y, Shi, W, Li, Y, Zhou, Y, Hu, X, Song, C, et al. Neuroprotective effects of chlorogenic acid against apoptosis of PC12 cells induced by methylmercury. Environ Toxicol Pharmacol 2008;26:13–21. https://doi.org/10.1016/j.etap.2007.12.008.
Sadeghnia, HR, Jamshidi, R, Afshari, AR, Mollazadeh, H, Forouzanfar, F, Rakhshandeh, H. Terminalia chebula attenuates quinolinate-induced oxidative PC12 and OLN-93 cell death. Mult Scler Relat Disord 2017;14:60–7. https://doi.org/10.1016/j.msard.2017.03.012.
Elyasi, L, Eftekhar-Vaghefi, SH, Asadi-Shekaari, M, Esmaeili-Mahani, S. Induction of cross-tolerance between protective effect of morphine and nicotine in 6-hydroxydopamine-induce neurotoxicity in SH-SY5Y human dopaminergic neuroblastoma cells. Int J Neurosci 2019;129:129–38. https://doi.org/10.1080/00207454.2018.1494169.
Faivre, F, Sánchez-Catalán, MJ, Dovero, S, Bido, S, Joshi, A, Bezard, E, et al. Ablation of the tail of the ventral tegmental area compensates symptoms in an experimental model of Parkinson’s disease. Neurobiol Dis 2020;139:104818. https://doi.org/10.1016/j.nbd.2020.104818.
Duchen, MR. Mitochondria, calcium-dependent neuronal death and neurodegenerative disease. Pflueg Arch Eur J Physiol 2012;464:111–21. https://doi.org/10.1007/s00424-012-1112-0.
Lin, G, Sun, Y, Long, J, Sui, X, Yang, J, Wang, Q, et al. Involvement of the Nrf2-Keap1 signaling pathway in protection against thallium-induced oxidative stress and mitochondrial dysfunction in primary hippocampal neurons. Toxicol Lett 2020;319:66–73. https://doi.org/10.1016/j.toxlet.2019.11.008.
Dong, X-X., Wang, Y, Qin, Z-H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin 2009;30:379. https://doi.org/10.1038/aps.2009.24.
Hurley, MJ, Brandon, B, Gentleman, SM, Dexter, DT. Parkinson’s disease is associated with altered expression of CaV1 channels and calcium-binding proteins. Brain 2013;136:2077–97. https://doi.org/10.1093/brain/awt134.
Sandebring, A, Dehvari, N, Perez-Manso, M, Thomas, KJ, Karpilovski, E, Cookson, MR, et al. Parkin deficiency disrupts calcium homeostasis by modulating phospholipase C signalling. FEBS J 2009;276:5041–52. https://doi.org/10.1111/j.1742-4658.2009.07201.x.
Mosharov, EV, Larsen, KE, Kanter, E, Phillips, KA, Wilson, K, Schmitz, Y, et al. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009;62:218–29. https://doi.org/10.1016/j.neuron.2009.01.033.
Surmeier, DJ, Guzman, JN, Sanchez-Padilla, J, Schumacker, PT. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson’s disease. Neuroscience 2011;198:221–31. https://doi.org/10.1016/j.neuroscience.2011.08.045.
Giorgi, C, Baldassari, F, Bononi, A, Bonora, M, De Marchi, E, Marchi, S, Missiroli, S, et al. Mitochondrial Ca2+ and apoptosis. Cell Calcium 2012;52:36–43.
Smaili, S, Hirata, H, Ureshino, R, Monteforte, PT, Morales, AP, Muler, ML, et al. Calcium and cell death signaling in neurodegeneration and aging. An Acad Bras Cienc 2009;81:467–75. https://doi.org/10.1590/s0001-37652009000300011.
Karn, A, Zhao, C, Yang, F, Cui, J, Gao, Z, Wang, M, et al. In-vivo biotransformation of citrus functional components and their effects on health. Crit Rev Food Sci Nutr 2020:1–21. https://doi.org/10.1080/10408398.2020.1746234.
Yu, X, Li, X, Jiang, G, Wang, X, Chang, HC, Hsu, WH, et al. Isradipine prevents rotenone-induced intracellular calcium rise that accelerates senescence in human neuroblastoma SH-SY5Y cells. Neuroscience 2013;246:243–53. https://doi.org/10.1016/j.neuroscience.2013.04.062.
Wickenden, AD, Krajewski, JL, London, B, Wagoner, PK, Wilson, WA, Clark, S, et al. N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator. Mol Pharmacol 2008;73:977–86. https://doi.org/10.1124/mol.107.043216.